Sanofi shares phase 3 trial results for Sarclisa in multiple myeloma treatment
Betsy Goodfellow | June 5, 2024 | News story | Research and Development | Oncology, Sanofi, Sarclisa, clinical trial, multiple myeloma
Sanofi has announced data from the IMROZ phase 3 trial which assessed Sarclisa (isatuximab) in combination with standard-of-care bortezomib, lenalidomide and dexamethasone (VRd) followed by Sarclisa-Rd, compared to VRd followed by Rd for the treatment of patients with newly diagnosed multiple myeloma (NDMM) not eligible for transplant.
The trial demonstrated that Sarclisa reduced the risk of disease progression or death by 40% compared to standard of care, indicating its ability to significantly improve progression-free survival (PFS), therefore meeting its primary endpoint.
The full results were shared in an oral presentation at the American Society of Clinical Oncology (ASCO) annual meeting as well as being published in The New England Journal of Medicine.
Thierry Facon MD, professor of haematology in the department of haematology at Lille University Hospital, France, member of the French Academy of Medicine and IMROZ principal investigator, commented: “The significant PFS benefit observed with Sarclisa combination therapy compared to VRd is important and encouraging for patients with NDMM. Effective frontline therapy has the potential to modify the course of the disease, which is a key outcome for transplant-ineligible patients who often face high rates of attrition in later lines of therapy. The IMROZ results demonstrate the promise of Sarclisa as a backbone to frontline therapy, which may improve long-term outcomes for this incurable disease.”
Betsy Goodfellow
Related Content
Sanofi and Regeneron’s Dupixent receives CHMP recommendation for chronic spontaneous urticaria
Sanofi and Regeneron have received a positive opinion from the European Medicines Agency’s (EMA) Committee …
UCB announces first-in-patient trial success for galvokimig in atopic dermatitis
UCB has reported positive early clinical trial results for galvokimig, an investigational therapy for adults …
FDA approves Wegovy for treatment of MASH in adults with liver fibrosis
The US Food and Drug Administration (FDA) has granted accelerated approval for Wegovy (semaglutide) as …
